Thailand is emerging as a popular destination for patients considering stem cell therapy to support diabetes management. In this piece, we look at what MSC-based therapies are really targeting — chronic inflammation and endothelial dysfunction as well as circulatory impairment – why tackling these mechanisms should be equally important to diabetic health in the longer-term alongside blood sugar control.
The majority of those conversations around managing diabetes starts and ends with glucose. Skewed blood sugar readings, HbA1c targets and insulin sensitivity are the headline metrics dominating clinical appointments or patients anxiety alike. They matter, of course. But for the impact on what diabetes does to other parts of the body you need those blood sugar readings. And more recently an ever bigger wave of these patients arriving at specialist clinics in Thailand are asking a different question altogether: what else can be done?
One of the more serious interests in Thailand’s regenerative medicine sector is a form of stem cell therapy — mesenchymal stem cells (MSCs) derived from umbilical cord tissue, bone marrow or adipose fat. Not as a substitute for traditional diabetes treatment; but rather, it is an adjunct whose bio-function that conventional pharmacotherapy often fails to reach.
Figure 1: Stem Cell Therapy for Diabetes in Thailand: Supporting Inflammation, Circulation, and Tissue Health Beyond Blood Sugar
Diabetes Is an Inflammatory Disease
This is a fact that gets less emphasis than it deserves. A metabolically neutral environment is not one which leads to the development of type 2 diabetes. And grows in a state of chronic low-grade systemic inflammation. The pro–-inflammatory cytokines secreted from visceral adipose tissue inhibit the signalling of insulin receptors. Progressive beta-cell dysfunction due to activated macrophages in the pancreatic islets. At the cellular level, insulin resistance is exacerbated by oxidative stress.
This inflammatory context explains why even patients with perfectly controlled blood sugar progress down a road of complications. Improving glycaemic control treats a disease symptom — it does not extinguish the inflammatory engine. In this regard, MSC therapy serves to modulate that engine via paracrine release of anti-inflammatory cytokines (IL-10 and TGF-β), suppression of overzealous activity by the unitary T-cell and macrophage components driving inflammation processes toward scarring instead of repair, and upregulation through numerous mechanisms yet fully characterized drive in innate antioxidant pathways.
No, Wait And Circulatory Complications No One Talks About Enough
Chronic diabetes is associated with some of the most pernicious sequelae including peripheral vascular disease, diabetic neuropathy and delayed wound healing – that are caused in large part by circulatory defects. Chronic hyperglycaemia results in endothelial damage, decreased nitric oxide bioavailability and has been shown to impair the body’s capacity for angiogenesis; formation of new blood vessels as a response to tissue ischaemia.
When patients have numbness in their feet, ulcers that heal slowly or early manifestations of peripheral arterial disease，good Control over glycaemia alone is rarely able to undo the mechanical changes already set. This is exactly where MSC-based approaches began to provide some of those most clinically meaningful signals early on in their preclinical pathways.
MSCs express and secrete vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF)—molecules that directly stimulate angiogenesis as well as endothelial repair. Studies have demonstrated that the injection of MSC into spontaneous foot ulcers promoted peripheral perfusion, lowered neuropathic symptom scores and achieved rapid healing in diabetic animals. These are not trivial outcomes. They are an entirely new quality of life for someone with a limb on the chopping block.
Why Thailand Became A Destination for This Care
Thailand has seized a unique position in the landscape of global regenerative medicine as it benefits from internationally trained physicians, well-established clinical infrastructure and an approachable regulatory stance that allows for some stem cell therapies to be performed (approved) within accredited hospitals.
There are a number of clinics and hospital programmes in Bangkok, in particular Chiang Mai offering MSC-based protocols for the treatment of metabolic conditions including what appears to be either an IV or tissue targetted infusion followed by intensive lifestyle/nutritional/pharmacological support. The quality of care at leading Thai centres now rivals equivalent programmes in South Korea, Germany and the United States.
Patients contemplating treatment in Thailand should search for centres which are recognised by larger hospitals with endocrinologists and regenerative medicine specialists working actually collaboratively, where protocols and report outcomes data transparently. Be cautious of any centre who is unable to provide this.
Realistic Expectations for Patients
Diabetes is not curable so when there are people who offer this service at a Thai centre, it does NOT mean that they cure. Instead, the well-designed programmes would provide a biologically consistent response to those features of diabetes — chronic inflammation (with signalling cytokines), vascular dysfunction and beta-cell stress — which standard drug therapy fails fully to address.
Following MSC treatment patients have reported decreases in inflammatory markers, increased peripheral sensation and accelerated wound healing as well modest improvements with respect to insulin sensitivity. They are not assured, nor the same for every patient or at every stage of disease. The best candidates appear to be patients at the earliest stages of type 2 diabetes with established inflammatory and vascular disease who are also commiteed to diet, exercise, and pharmacotherapy.
Summarise
The long-term approach to diabetes management needs to go beyond a blood glucose number measured in a glucometer, and enrol the complete biological complexity of this condition. Stem cell therapy, when responsibly offered and administered as part of a comprehensive care package could be that serious attempt at doing this. Thailand is providing patients the best use of that wider framework.
The dialogue that is evolving around diabetes. Blood glucose was competing the whole time And for patients old enough to know what a CRP blood test is: the future of how else we might treat chronic pain deserves an evidence-informed answer and increasingly that answer can be explored in clinics across Thailand.
References
Bhansali, A., Upreti, V., Khandelwal, N., et al. (2009). Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells and Development, 18(10), 1407–1416.
Esposito, K., Nappo, F., Marfella, R., et al. (2002). Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation, 106(16), 2067–2072.
Lian, Q., Lye, E., Yeo, K.S., et al. (2007). Derivation of clinically compliant MSCs from CD105+CD24- differentiated human ESCs. Stem Cells, 25(2), 425–436.
Skyler, J.S., Fonseca, V.A., Segal, K.R., & Rosenstock, J. (2015). Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care, 38(8), 1415–1422.
Weiss, A.R.R., & Dahlke, M.H. (2019). Immunomodulation by mesenchymal stem cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. Frontiers in Immunology, 10, 1191.